18F-FDG PET/CT in Tumors of the Gastrointestinal Tract: Esophageal and Gastric Cancer and Gastrointestinal Stromal Tumors (GIST)



Esophageal cancer is the eighth leading cause of cancer with a worldwide estimate of more than 400,000 new cases annually. It is the third most common gastrointestinal malignancy, with a highly variable incidence in different geographic locations. While in the United States and Western Europe less than 5/100,000 individuals suffer from this disease, its incidence is steadily increasing over recent years in these countries.1–3


Positron Emission Tomography Esophageal Cancer Standardize Uptake Value National Comprehensive Cancer Network Complete Metabolic Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Plukker JT, van Westreenen HL. Staging in oesophageal cancer. Best Pract Res Clin Gastroenterol 2006;20:877–891.CrossRefPubMedGoogle Scholar
  2. 2.
    Bombardieri E. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging 2006;33:753–758.CrossRefPubMedGoogle Scholar
  3. 3.
    Das A, Chak A. Reassessment of patients with esophageal cancer after neoadjuvant therapy. Endoscopy 2006;381:S13–17.CrossRefGoogle Scholar
  4. 4.
    Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006;82:391–395.CrossRefPubMedGoogle Scholar
  5. 5.
    McDonough PB, Jones DR, Shen KR, Shen R, Northup P, Hernandez A, White G, Kahaleh M, Shami V. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study. Am J Gastroenterol 2007;65:AB136–AB136.Google Scholar
  6. 6.
    Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan T-S, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: Its role in clinical management. Radiographics 2007;27:1635–1652.CrossRefPubMedGoogle Scholar
  7. 7.
    Wong WL, Chambers RJ. Role of PET/CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: A literature review. Abdom Imaging 2008;33:183–190.CrossRefPubMedGoogle Scholar
  8. 8.
    Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, Landreneau RJ, Reed CE, Balfe DM, Dehdashti F, Ballman KV, Rusch VW, Putnam JB Jr; American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the american college of surgeons. Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007;133:738–745.CrossRefPubMedGoogle Scholar
  9. 9.
    Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, Ben-Nun A, Keidar Z, Israel O. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2005;32:918–924.CrossRefPubMedGoogle Scholar
  10. 10.
    Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Liu T, Chen S, Yang X, Yang G, Guo H Yu J. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 2006;47:1255–1259.PubMedGoogle Scholar
  11. 11.
    Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202–3210.PubMedGoogle Scholar
  12. 12.
    Duong CP, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJ, Hicks RJ. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:759–769.CrossRefPubMedGoogle Scholar
  13. 13.
    Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006;19:433–442.CrossRefPubMedGoogle Scholar
  14. 14.
    van Westreenen HL, Westerterp M, Sloof GW, Groen H., Bossuyt PMM, Jager PL, Comans EF, van Dullemen HM, Fockens P, Stoker J, van der Jagt EJ, van Lanschot JJB, Plukker JT. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94:1515–1520.CrossRefPubMedGoogle Scholar
  15. 15.
    Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, Reed CE. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002;74:1026–1032.CrossRefPubMedGoogle Scholar
  16. 16.
    Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, Meltzer CC. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133–1136CrossRefPubMedGoogle Scholar
  17. 17.
    Siersema PD. Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Curr Opin Gastroenterol 2007;23:456–461.CrossRefPubMedGoogle Scholar
  18. 18.
    Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BLF, Plukker JT, van Lanschot JJB, Sloof GW. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy – systematic review. Radiology 2005;236:841–851.CrossRefPubMedGoogle Scholar
  19. 19.
    Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007;109:125–134.CrossRefPubMedGoogle Scholar
  20. 20.
    Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D, Mortelmans L. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000;120:1085–1092.CrossRefPubMedGoogle Scholar
  21. 21.
    Guo H, Zhu H, Xi Y, et al. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 2007;48:1251–1258.CrossRefPubMedGoogle Scholar
  22. 22.
    Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park M-S, Choi J-Y, Kim T-S, Lee JD, Noh SH, Kim KW. CT and PET in stomach cancer: Preoperative staging and monitoring of response to therapy. Radiographics 2006;26:143–156.CrossRefPubMedGoogle Scholar
  23. 23.
    Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H, Kanamaru R. Evaluation of 18F-FDG PET in patients with metastatic or recurrent gastric cancer. J Nucl Med 2003;44:690–699.PubMedGoogle Scholar
  24. 24.
    Wu MS, Yang KC, Shun CT, Hsiao TJ, Lin C-C, Wang H-P, Chuang S-M, Lee W-J, Lin J-T. Distinct clinicopathologic characteristics of diffuse- and intestinal-type gastric cancer in Taiwan. J Clin Gastroenterol 1997;25:646–649.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: Relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006;20:597–604.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383–2390.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, Lee JH, Ryu KW, Kim Y-W, Bae J-M. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148–155.CrossRefPubMedGoogle Scholar
  28. 28.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni, RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002;224:748–756.CrossRefPubMedGoogle Scholar
  29. 29.
    Ott K, Fink U, Becker K, Stahl A, Dittler H-J, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert J-R, Weber WA. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 2003;21:4604–4610.CrossRefPubMedGoogle Scholar
  30. 30.
    Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007;8:797–805.CrossRefPubMedGoogle Scholar
  31. 31.
    De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, Maes A, Mortelmans L. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525–529.CrossRefPubMedGoogle Scholar
  32. 32.
    Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215–221.CrossRefPubMedGoogle Scholar
  33. 33.
    Rosen RS, Fayad L, Wahl RL. Increased 18F-FDG uptake in degenerative disease of the spine: characterization with 18F-FDG PET/CT. J Nucl Med 6;47:1274–1280.Google Scholar
  34. 34.
    Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545–2551CrossRefPubMedGoogle Scholar
  35. 35.
    Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom L-G. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 2005;103:821–829.CrossRefPubMedGoogle Scholar
  36. 36.
    Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002;3:655–664.CrossRefPubMedGoogle Scholar
  37. 37.
    Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705–712.CrossRefPubMedGoogle Scholar
  38. 38.
    Goerres GW, Stupp R, Barghouth G, Hany TG, Pestalozzi B,  Dizendorf E,  Schnyder P,  Luthi F,  von  Schulthess JK, Leyvraz S. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumors: Long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153–162.CrossRefPubMedGoogle Scholar
  39. 39.
    Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, Oriuchi N, Endo K. 18F-fluorodeoxyglucose positron emission tomography: Useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005;29:1429–1435.CrossRefPubMedGoogle Scholar
  40. 40.
    Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A.18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Gleevec®). Eur J Cancer 2003;39:2012–2020CrossRefPubMedGoogle Scholar
  41. 41.
    Grimpen F, Yip D, McArthur G, Waring P, Goldstein D, Loughrey M, Beshay V, Chong G. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumor. Lancet Oncol 2005;6:724–727.CrossRefPubMedGoogle Scholar
  42. 42.
    Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753–1459.CrossRefPubMedGoogle Scholar
  43. 43.
    Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006;32:961–963.CrossRefPubMedGoogle Scholar
  44. 44.
    Choi H, Charnsangavej C, de Castro Faria S, Tamm EP,. Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183:1619–1628.PubMedGoogle Scholar
  45. 45.
    Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types Task Force. J Natl Compr Canc Netw 2009;7 Suppl 2: S1–S23. www.nccn.org/professionals/physician_gls/f_guidelines.asp PubMedGoogle Scholar
  46. 46.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations for the use of FDG (fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008; 49:480–508.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Rambam Health Care CampusB. and R. Rappaport School of Medicine, Technion—Israel Institute of TechnologyHaifaIsrael
  2. 2.Departments of Diagnostic ImagingRambam Health Care CampusHaifaIsrael

Personalised recommendations